Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063582 | 1.00 | ELANE (0.36) | ELANEF2CTSGALDH1A1TSHR | |
| SCHEMBL6063849 | 0.84 | ABCB1 (0.44) | ELANEF2CTSGRIPK1 | |
| SCHEMBL6161927 | 0.84 | GSTP1 (0.38) | ALDH1A1MDM2 | |
| SCHEMBL6161924 | 0.84 | GSTP1 (0.38) | ALDH1A1MDM2 | |
| SCHEMBL6918361 | 0.81 | ELANE (0.35) | ELANEALDH1A1TSHRGAAATM | |
| SCHEMBL22636048 | 0.81 | ELANE (0.35) | ELANEALDH1A1TSHRGAAATM | |
| SCHEMBL7063555 | 0.76 | MAPT (0.32) | ELANEALDH1A1MDM2ATMSMN1; SMN2 | |
| SCHEMBL6835149 | 0.76 | LMNA (0.34) | MDM2SMN1; SMN2NPSR1 | |
| SCHEMBL28496124 | 0.75 | LIPG (0.33) | MDM2 | |
| SCHEMBL1728341 | 0.75 | RIPK1 (0.34) | ELANEF2CTSGALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008957-B2 | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | ELANE 3948/4885F2 873/4885CTSG 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.